Novelwise Pharma Secures Exclusive Global License from National Cheng Kung University

Novelwise Pharma Corp. announced that it has secured an exclusive global license from National Cheng Kung University (NCKU) for the patent portfolio titled “PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING GLIOBLASTOMAS.” The license grants the company full rights to use, develop, manufacture (including subcontracted manufacturing), market, and import products derived from the patented technology, strengthening its foundation in nucleic acid therapeutics and precision oncology.

Under the agreement, Novelwise Pharma will provide an upfront license fee and milestone payments linked to R&D progress, followed by royalties based on net sales once products reach commercialization. This collaboration ensures sustained recognition of the patent's value while paving a clear path for global market entry.

Novelwise Pharma stated that the license will further strengthen its R&D capabilities in nucleic acid drugs and precision cancer therapeutics, while also broadening applications to diagnostics and mechanistic visualization. By deepening academia-industry collaboration, the company aims to accelerate clinical translation, expand its international footprint, create sustainable competitive advantages, and deliver long-term value for patients, partners, and stakeholders.